Brought to you by 
Novartis' Sandoz buys Fougera Pharmaceuticals for $1.53bn in cash
23 Jul 2014
Executive Summary
Novartis AG’s Sandoz division has acquired closely held generics dermatology firm Fougera Pharmaceuticals Inc. from a consortium of PE funds (led by Nordic Capital Funds, DLJ Merchant Banking Partners, and Avista Capital Partners) for $1.53bn in cash.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis' Sandoz buys Fougera Pharmaceuticals for $1.53bn in cash
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice